Australia markets open in 4 hours 55 minutes

Novavax, Inc. (NVAX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
6.53+0.37 (+5.93%)
As of 02:05PM EDT. Market open.

Novavax, Inc.

21 Firstfield Road
Gaithersburg, MD 20878
United States
240 268 2000
https://www.novavax.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees1,992

Key executives

NameTitlePayExercisedYear born
Mr. James Patrick Kelly C.F.A.Exec. VP, CFO & Treasurer355.23kN/A1966
Mr. John A. Herrmann IIIExec. VP, Chief Legal Officer & Corp. Sec.657.8k14.2M1966
Mr. Stanley Charles ErckAdvisor1.12M28.63M1948
Mr. John Joseph Trizzino B.S., M.B.A.Exec. VP and Chief Bus. & Commercial Officer636.85k13.33M1960
Dr. Gregory M. Glenn M.D.Pres of R&D813.44k29.02M1954
Mr. John Charles Jacobs M.B.A.Pres, CEO & DirectorN/AN/A1968
Mr. Richard P. CrowleyExec. VP & COON/AN/A1957
Dr. Gale E. SmithSr. VP of Discovery & Pre-Clinical Research and Chief ScientistN/AN/A1950
Mr. Biegie LeeSr. VP & Chief Information OfficerN/AN/AN/A
Mr. Troy Morgan Esq., J.D.Sr. VP & Chief Compliance OfficerN/AN/A1971
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, Adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also focusing on products candidates for respiratory syncytial virus and malaria. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Corporate governance

Novavax, Inc.’s ISS governance QualityScore as of 1 March 2023 is 5. The pillar scores are Audit: 7; Board: 6; Shareholder rights: 5; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.